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ABSTRACT 
 
Objective: 
The objective of this selective EBM review is to determine “Are linoleic acid supplements 
beneficial in increasing growth in pediatric cystic fibrosis patients?” 
 
Study Design: 
Review of three English primary studies published between 1995 and 2000. 
 
Data Sources: 
Two randomized control trial and one controlled clinical trial were used. 
Studies were found using PubMed and Cochrane Databases. 
 
Outcomes Measured: 
Primary outcomes measured include the taste, smell, and appearance of the supplement and the 
growth of the cystic fibrosis patients. 
 
Results: 
In Steinkamp G, Demmelmair et al., the treatment group grew in its weight-for-height; whereas, 
there was no change in the growth/ body weight of the control group.  Furthermore, the treatment 
group had an overall weight gain of 1.2 kg.  In van Egmond et al., the participants using the 
supplement with more linoleic acid grew better than those using a supplement with less linoleic 
acid.  In Rettammel AL, Marcus MS et al, fifteen of the twenty-four participants used an oral 
supplement before and ten of those individuals preferred this supplement.  The supplement was 
well tolerated with fourteen participants preferring the taste of the supplement; however, seven 
participants thought the supplement was inconvenient and reported that the supplement was 
difficult to reconstitute. 
 
Conclusions: 
The results of the two randomized control trials and a controlled clinical trial demonstrated that 
linoleic acid supplements increase growth in pediatric cystic fibrosis individuals.  Future study is 
warranted to evaluate the proper amount of linoleic acid needed to increase growth, and different 
techniques need to be carried out in order to improve the taste and convenience of the 
supplement.  The trials were not double blind studies and had a small sample size, which may 
have limited the data formulated. 
 
Keywords: 
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Introduction 
 Cystic Fibrosis (CF) is an inherited, life-threatening disease that causes the body to 
produce high levels of mucus, primarily affecting the lungs and pancreas.
1  
In addition to 
hindering an individual’s breathing, the mucus obstructs the pancreas and decreases the release 
of pancreatic enzymes which stops the body from breaking down and absorbing food.
2  
Various 
symptomatic treatments have aided patients in their ability to breathe easier and to thin copious 
amounts of their mucous production; however, considerations of the metabolic disturbances are 
vital in their management as well.  One such supplement, linoleic acid, can be beneficial and 
effective in the growth of pediatric cystic fibrosis patients.  
 The incidence of CF is approximately 1,000 new cases each year affecting 30,000 people 
in the United States and 70,000 people globally.  The ratio of an individual being a carrier of this 
disease to a non-carrier is 1:31 American families.
2  
The treatment for CF is approximately 
$50,000- $74,000 per year.
3 
The number of healthcare visits each year is unknown because it 
varies based on the severity of a patient’s disease.  There are multiple routine visits each year, 
but some patients may need to be hospitalized based on their exacerbations and lung function.
2 
The CF gene “makes a protein called the CF Transmembrane conductance Regulator 
(CFTR), which is a chloride channel.”4 This channel allows Chloride followed by water to flow 
out of the cells and keeps the mucus thin as it travels out of the lungs.  CF is caused by a 
defective gene of the CFTR, which produces copious, adhesive-like mucus secreted over the 
lungs, pancreas and reproductive system.  Due to the increased mucus secretion over the lungs, 
CF individuals will attract bacteria and have numerous lung infections.  Furthermore, the thick 
secretions can obstruct the pancreas and prevent necessary enzymes from being produced during 
digestion leading to poor growth and reduced nutrition.
2
  Common symptoms include salty skin, 
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cough, unctuous stools, wheeziness and shortness of breath.  Even though the cause of CF is 
known, there is not a definite cure.  The CF foundation has made strides in its funding and 
researching in order to prolong the quality and quantity of life.   
The usual methods to treat CF are symptomatic. The mainstay treatments are airway 
clearing (postural drainage/ percussion, or inflatable vests) and nutrition supplements, such as a 
high calorie diet, pancreatic enzyme replacements, and vitamin D.  Additional treatment 
regimens consist of inhaled medications, bronchodilators, mucolytics, hypertonic saline, and 
antibiotics, such as Azithromycin, Tobramycin, or Ciprofloxacin.  Depending on the severity of 
the illness, an individual may need nasal polyp removals, a lung transplant, oxygen therapy, or a 
feeding tube.
2  
New treatments are currently in trials that are meant to treat the underlying cause 
of CF.  Since the risk of malnutrition is high in individuals with CF, Linoleic
 
acid supplements 
may be used to aid in the growth of CF individuals.  Those with malnutrition have a deficiency 
in essential fatty acids which can decrease their overall health leading to poorer outcomes. 
Energy rich supplements containing linoleic acid may be beneficial in the treatment regimen of 
those with CF.  This selective evidence-based medicine review evaluated two randomized 
control trials and one controlled clinical trial to examine the growth of pediatric cystic fibrosis 
individuals taking linoleic acid supplements. 
Objective 
The objective of this selective EBM review is to determine “Are linoleic acid 
supplements are beneficial in increasing growth in pediatric cystic fibrosis patients?” 
Methods 
The criteria used for the selection of studies included pediatric CF patients with significantly low 
body weight.  The intervention studied in one randomized control trial consisted of an oral 
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energy supplement containing linoleic acid with dietary counseling; whereas the other 
randomized control trial used predigested formula containing 12% of total energy of linoleic 
acid.  The controlled clinical trial consisted of a powder nutrition supplement with more energy, 
fat and linoleic acid.  The first randomized control trial compared a control group of cystic 
fibrosis patients receiving dietary counseling only; whereas the second randomized control trial 
compared predigested formula containing 7% of total energy of linoleic acid.  The controlled 
clinical trial compared the individuals enrolled in this study to their own results before and after 
the use of the supplement. Measured outcomes that are being utilized are the taste, smell, and 
appearance of the supplement and the growth of the patients. The study types involved two 
randomized control trials and one controlled clinical trial.  
Key words used to acquire literature included “linoleic acid supplements,” “cystic 
fibrosis,” “pediatrics,” and “malnutrition.”  All articles were published in peer reviewed journals 
and all were in the English language.  The articles were all searched by the author through 
PubMed and Cochrane Databases.  They were selected based upon their relevance and 
importance to patient oriented evidence that matters (POEMS).  Inclusion criteria consisted of 
studies that were randomized controlled and included patient-oriented outcomes.  Also, the 
inclusion criteria consisted of individuals with cystic fibrosis that have a significantly low body 
weight below 95% of normal for height.  Exclusion criteria consisted of those who were older 
than 18 years of age and articles that addressed disease-oriented evidence (DOE).   Statistics 
were reported based on p-values and standard deviation.   Table 1 demonstrates the 
demographics and characteristics of the included studies.
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Table 1 – Demographics and Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Steinkamp 
(2000)
5 
RCT 36 > 4 
years 
old 
Patients with CF 
that have low 
body weight 
-Patients less 
than 4 years old 
-Patients with 
DM or liver 
cirrhosis 
-Received 
oxygen therapy 
or nocturnal 
gastrostomy 
feeding 
0 An oral 
energy 
supplement 
containing 
linoleic acid 
with dietary 
counseling.  
Rettammel 
(1995)
1 
Controlled 
Clinical 
Trial 
24 >4 years 
old 
Patients with 
either a decrease 
in one growth 
channel in 
weight for age 
during the 
previous year, a 
plateau in 
weight gain for 
3 months or 
longer, or an 
adequate growth 
dependent on 
prescribed 
nutritional 
supplement 
Patients that 
have not been 
diagnosed with 
pancreatic 
insufficiency 
7 A powder 
nutrition 
supplement 
with more 
energy, fat 
and linoleic 
acid that was 
taken at least 
once a day 
depending on 
the age of the 
individual.  
van 
Egmond 
(1996)
6 
RCT 76 Infants 
followed 
for 9 yrs 
-A patient at 
University of 
Wisconsin 
-Diagnosed by 9 
months of age 
and had dietary 
records 
indicating they 
were fed 
predigested 
formula 
Infants that had 
been breast fed 
11 Predigested 
formula 
containing 
12% of total 
energy of 
linoleic acid. 
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Outcomes Measured 
 Each of the three trials assessed the effect of linoleic acid supplements on the growth of 
the cystic fibrosis individuals and/or the acceptability and tolerance of the supplement.  The 
growth of the individuals was measured by height and weight. Van Egmond et al. assessed the 
growth outcome by measuring the individuals’ weight-for-age (WAZ) and height-for-age (HAZ).  
The ANTHRO software was used to calculate the Z scores.
6 
 Rettammel AL, Marcus MS et al 
assessed the taste, smell and appearance of the supplement that was measured by a questionnaire.  
The questionnaire rated the taste, smell, appearance and mouth feel of the supplement on a scale 
of “poor-fair-good-excellent.”1  Also, the trial measured growth by calculating Z scores using the 
CASP program.
1 
Results 
 Two trials evaluated the efficacy of linoleic acid supplements on the growth of 
individuals with cystic fibrosis.  The randomized control trials compared linoleic acid 
supplements to a supplement reduced in linoleic acid or strictly dietary counseling; whereas the 
controlled clinical trial compared the growth before and after the intervention.  
The randomized control trial (Steinkamp G, Demmelmair et al.) compared the use of an oral 
supplement containing linoleic acid with an addition of dietary counseling to a control group of 
cystic fibrosis patients receiving dietary counseling only.  This was a three month long trial that 
included patients with CF that have significantly low weight-for-height below 95%.  It excluded 
patients less than four years old, those with diabetes mellitus, or liver cirrhosis and individuals 
who received oxygen therapy or nocturnal gastrostomy feeding.  There were thirty-six 
participants and none of the individuals discontinued the trial.  The participants’ height and 
weight were measured before the intervention and after the three month trial.  The dietary 
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counseling was given to all participants at the baseline visit.  Sixteen patients were randomly 
chosen to enter the treatment group; whereas twenty were chosen for the comparison group.  In 
order to compare baseline and post treatment values, paired t-tests were completed, and grouped 
t-tests were carried out for the comparison groups.
5  
Finally, the results were shown to be 
statistically significant with a p value < 0.05.  The treatment group grew in its weight-for-height; 
whereas, there was no change in the growth/ body weight of the control group.  Furthermore, the 
treatment group had an overall weight gain of 1.2 kg. 
Table 2: Treatment vs. Control Group
5 
 Supplemented group (N=16) Comparison group (N=20) p-value 
Before After Before After < 0.05 
Length (cm) 147 + 15 
 
148 +16 135 + 22 136 + 21 
Weight (kg) 32.2 + 8.9 33.4 + 9.6 27.3 + 7.6 27.5 + 7.5 
Weight-for-height 
(% of predicted) 
82.8 + 8.6 84.8 + 9.6 87.8 + 8.7 85.6 + 10 
Body fat (kg) 5.1 + 1.7 5.8 + 2.2 4.4 + 1.6 4.3 + 1.4 
 
The other randomized control trial (van Egmond et al.) compared the use of predigested 
formula containing 12% of total energy linoleic acid (formula A) to predigested formula 
containing 7% of total energy of linoleic acid (formula B).  This was a longitudinal study that 
lasted for nine years.  In order to be included in the study, the participants had to be patients at 
the University in Madison or the Children’s Hospital of Wisconsin in Milwaukee, diagnosed by 
9 months of age and were fed predigested formula.  The exclusion criteria consisted of infants 
that had been breast-fed.  There were 76 infants who began the study and 11 participants 
discontinued.  The comparison of the formula containing 12% linoleic acid to 7% of linoleic acid 
assessed the growth of the participants which were measured by their height and weight at 
diagnosis and subsequent times defined by the various protocols (i.e. ages 1.5, 3, 4.5, 6, 7.5, 9, 
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10.5, 12, and 15 months).  The height, weight and Z scores were calculated by using the 
ANTHRO software.
6
  Even though forty-three participants were fed formula A and 33 were fed 
formula B, there were no significant differences between the two groups at baseline. Participants 
using formula A grew better than participants using formula B and was statistically significant 
for the height-for-age Z scores with a p value of 0.049.  However, the results for the weight-for-
age Z scores were not statistically significant with a p value of 0.081.   
Table 3: HAZ and WAZ scores at follow-up during infancy
6 
 Height-for-age Z score Weight-for-age Z score 
SD 1.18 0.98 
Mean -0.24 -0.74 
P value 0.049 0.081 
 
The controlled clinical trial (Rettammel AL, Marcus MS et al.) compared the taste, smell, 
and appearance of the linoleic acid supplement and growth of CF patients.  The intervention 
consisted of a powder nutrition supplement with more fat, energy and linoleic acid that was taken 
at least once a day depending the patient’s age.  Participants ages 5-10 consumed one 8oz 
serving per day; ages 11-17 consumed two 8oz servings per day and ages 18 and older consumed 
three 8oz servings per day.  This was a three month long trial that included patients older than 
four years old that were not participating in other research protocols, and either had a decrease in 
growth in weight-for-age or weight-for-height, had a plateau in weight gain for three months or 
had an adequate growth dependent on the use of a prescribed nutrition supplement.
1 
This trial 
excluded those who had not been diagnosed with pancreatic insufficiency.  There were twenty-
four participants in the study and seven discontinued the trial due to noncompliance, a secondary 
diagnosis of muscular dystrophy, or an intolerability of the supplement because of a 
cholecystectomy or vomiting. Of the seventeen remaining participants, eleven were pediatric 
participants under the age of eighteen years old and six were older than eighteen years old.  The
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growth of the participants was measured by their height and weight at baseline and their final 
visit after their three month trial.  There was no change in weight for the adult participants, but 
there was a significant gain in weight seen in pediatric children (p value= 0.02).  There were “no 
significant changes in skinfold measurements of z scored for weight and height.”1  However, one 
pediatric participant had an individual growth improvement with a weight gain of 2.5 kg and a 
4.4 cm increase in height. 
Furthermore, the participants used a questionnaire in order to discuss the overall taste and 
acceptability of the supplement. Even though seven subjects discontinued the trial, all twenty-
four subjects were included in the questionnaire. Fifteen of the twenty-four participants used an 
oral supplement before and ten of those individuals preferred this supplement.  Overall, the 
supplement was well tolerated with fourteen participants preferring the taste of the supplement. 
Four participants reported mild nausea, fullness and bloating.  Seven participants thought the 
supplement was inconvenient and reported that the supplement was difficult to reconstitute. The 
compliance positively correlated with weight gain (r=0.98) with the mean compliance of 69%.  
Table 4: Acceptance and Tolerability of the Supplement
1 
 Taste Smell Appearance Mouth feel 
Poor 3 0 0 6 
Fair 7 12 11 10 
Good 13 11 13 8 
Excellent 1 1 0 0 
 
Discussion 
 This selective EBM review investigated two randomized controlled trials and a controlled 
clinical trial for the efficacy of increasing growth in cystic fibrosis individuals and the 
tolerability of the linoleic acid supplement.  It is known that individuals with CF can become 
malnourished and have an overall decrease in growth.  Supplementing with linoleic acid, an
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omega-6 polyunsaturated fatty acid, was beneficial because the three trials demonstrated that the 
linoleic acid supplements did increase growth.  This data was statistically significant in the RCT 
by Steinkamp G, Demmelmair et al., and those receiving the supplement grew and benefited 
from the intervention.
5
  In van Egmond et al., infants consuming a formula with a larger content 
of linoleic acid grew more and had a higher weight gain.  Therefore, cystic fibrosis infants 
require a high intake of linoleic acid in order to achieve optimal growth.
6
  In Rettammel AL, 
Marcus MS et al., this supplement was shown to be tolerated and accepted by most; however, 
improving the reconstitution of the supplement in puddings, and other baked products may be 
beneficial for those who considered the supplement to be inconvenient.  
 There were several limitations among the trials presented in this selective EBM review, 
and few randomized control trials recently established narrowed the source for reference data.  
The two randomized control trials were not double blind studies.  Limitations in Rettammel AL, 
Marcus MS et al. include the small sample size, the variability, and the short three month time 
period.  Even though the three month trial period was an adequate time to define tolerability and 
acceptability of the supplement, it was not a sufficient time to determine growth of the 
participants.
1
  In van Egmond et al., a “time-bias of patient management” was considered a 
limitation in this trial.
6  
For all three trials, the results may have been influenced by these 
limitations. 
 Linoleic acid supplements have demonstrated to be advantageous in other disease states 
as well.  For example, linoleic acid supplements can be used in those who are deficient in 
linoleic acid, adult patients with end-stage liver disease, have hypertension or dermatitis.
7
  
Additionally, it is beneficial in improving premenstrual syndrome symptoms, multiple sclerosis, 
and neurodegenerative disorders.  Hypersensitivity to linoleic acid or its derivatives is a 
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contraindication.  Some adverse reactions include bloating, metabolic effects, or allergic 
inflammation.
7
 There is no teratogenicity data available, and Orlistat has been found to be a 
potential drug interaction because it decreases the absorption of linoleic acid.
7 
 Cystic fibrosis is a life- threatening disease that does not have a current cure; however, 
numerous funding and research has been accomplished to expand the quality and quantity of life.  
For example, Kalydeco was FDA approved in 2012 and is a new medication that treats CF 
individuals 6 years and older with the CF mutation G551D.
8
  It improves lung function and helps 
the patients gain weight by decreasing the sweat chloride levels.
8
 This medication has helped 
many people with CF with the particular mutation; however, it does not work for other 
mutations.  The CF foundation continues to explore different research topics and new 
medications in the hope of finding a cure for this disease.  Until a cure is possible, maintaining 
lung function, improving nutrition and preventing infections are the symptomatic mainstay 
treatment regimens.   
Conclusion
 
It is concluded that the three trials included in this selective EBM review determine that 
pediatric cystic fibrosis individuals can have an increase in growth with linoleic acid 
supplements.  Even though there were limitations in these trials, the participants did grow.  In 
addition to increasing the sample size and extending the time periods in the trials, future study is 
warranted to evaluate the proper amount of linoleic acid needed to increase growth.  Additional 
testing and experimentation are required in order to ascertain the appropriate weight of CF 
individuals at which the linoleic acid supplement would be more beneficial than increasing 
dietary intake.  Furthermore, various recipes or different blending techniques can be discussed in 
order to improve the taste and convenience of the supplement; however, it can be seen as a 
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positive addition as an oral nutritional supplement to cystic fibrosis treatment regimens.  Even 
though cystic fibrosis is incurable at this time, continued research and trials will only improve 
the quality of life of CF individuals and eventually find a cure for this disease. 
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